Age-related macular degeneration.
Section of Ophthalmology and Visual Science, Department of Surgery, University of Chicago, Chicago, USA. rjager@uretina.com
Rama D
RD
Jager
William F
WF
Mieler
Joan W
JW
Miller
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D004032:Diet; D018450:Disease Progression; D015316:Genetic Therapy; D006801:Humans; D015552:Injections, Intralesional; D017075:Laser Coagulation; D008268:Macular Degeneration / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D010778:Photochemotherapy; D000069579:Ranibizumab; D012160:Retina / Q000033:anatomy & histology / Q000473:pathology / Q000503:physiopathology; D015593:Retinal Drusen; D012307:Risk Factors; D016540:Smoking Cessation
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants; D000068258:Bevacizumab; D000069579:Ranibizumab